2018; 378(24):2288 - 301. PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 142Appendix 1. Abbreviations The following is a list of abbreviations that may be used in the protocol. Abbreviation Term Ab anti- body ABCP atezolizumab plus BCP AChR acetylcholine receptor ACRIN American College of Radiology Imaging Network ADA anti-drug antibodies AdC68 a chimpanzee adenovirus 68 AE adverse event AIDS acquired immunodeficiency syndrome ALK WT Anaplastic lymphoma kinase wild-type ALT alanine aminotransferase ANC absolute neutrophil count ANOVA analysis of variance ART antiretroviral therapy ASCO American Society of Clinical Oncology AST aspartate aminotransferase AUC area under the curve AUC inf area under the curve plasma concentration versus time curve from time 0 extrapolated to infinit y AUC last area under the curve plasma concentration following the first dose from time 0 to last time point BCP bevacizumab plus carboplatin plus paclitaxel BCT blood collection tube BID twice daily BP blood pressure BRAF proto-oncogene protein B-raf BSA body surface area BUN blood urea nitrogen C Cycle CAR chimeric antigen receptor CBR clinical benefit rate CL/F apparent serum clearance Cmax maximum plasma concentration C1D1 cycle 1 day 1 CHF congestive heart failure cHL classical Hodgkin lymphoma ChTx chemotherapy treatment CI confidence intervalCCI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 143Abbreviation Term CISH chromogenic in situ hybridization CK creatine kinase CL Clearance CLL chronic lym phocytic leukemia CNS central nervous system COVID-19 coronavirus disease of 2019 CR complete response CRF case report form CRM Continual Reassessment Method CSA clinical study agreement CSF cerebrospinal fluid CSR clinical study report CT computed tomography CT clinical trial CTA clinical trial application CTCAE Common Terminology Criteria for Adverse Events CTLA4 Anti-cytotoxic T Lymphocyte-associated antigen 4 cTnI cardiac troponin-I CV coefficient of variation DILI drug-induced liver injury DLI donor lymphocyte infusion DLT dose-limiting toxicit y DMC data monitoring committee DNA deoxyribonucleic acid DR duration of Response DU dispensable unit D/U dose de-escalation DOR duration of response DOSD duration of stable disease EC ethics committee ECC emergency contact card ECG Electrocardiogram ECOG Eastern Cooperative Oncology Group E-DMC external data monitoring committee EDP exposure during pregnancy EDTA ethylenediaminetetraacetic acid EFS event-free survival Eg for example EGFR epidermal growth factor receptor EI equivalence intervalCCI PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 144Abbreviation Term EML 4 echinoderm microtubule -associated protein -like 4 EP evaluable population ER estrogen receptor Etc ‘and other things’ or ‘and so forth’ EU European Union EudraCT European Clinical Trials Database FDA Food and Drug Administration (United States) FFPE formalin -fixed paraffin -embedded FIP first in patient FISH fluorescence in situ hybridization FSH follicle -stimulating hormone GCP Good Clinical Practice GGT gamma -glutamy l transferase GI gastrointestinal GnRH gonadotropin -releasing hormone agonist GPI glycophosphatidylinositol GVAX cancer vaccine GVHD graft versus host disease HBV hepatitis B virus HCC hepatocellular carcinoma HCV hepatitis C virus HER2 human epidermal growth factor 2 Hgb Hemoglobin HIV human immunodeficiency virus HR heart rate / hazard ratio IB investigator’s brochure ICH International Conference on Harmonisation ICOS inducible T -cell costimulatory ID Identification Ie that is IFN Interferon Ig Immunoglobulin IgG4 immunoglobulin G4 IHC immunohistochemistry IM intramuscular IP investigational product IND investigational new drug application INR international normalized ratio IP manual Investigational Product manual IRB institutional review board IRC internal review committee PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 145Abbreviation Term irCR immune related – complete response irPD immune related – progressive disease irPR immune related – partial response irSD immune related – stable disease IRT interactive response technology ISR injection site reaction IUD intrauterine device IV intravenous IWR interactive Web- based res ponse kDa kilodalton KRAS proto-oncogene LAG3 lymphocyte activation gene 3 LDH lactate dehydrogenase LFT liver function test LM listeria monocytogene LSLV last subject last visit LVEF left ventricular ejection fraction mAb monoclonal antibody MCC Merkel cell carcinoma MD multiple dose MedDRA Medical Dictionary for Regulatory Activities MFD maximum feasible dose MG myasthenia gravis MHC major histocompatibility complex mITT modified intend to treat mNSCLC metastatic non-small cell lung cancer mOS median overall survival MPF megakaryocyte potentiating factor mPFS median progression-free survival MRI magnetic resonance imaging MSLN mesothelin MTD maximum tolerated dose mTNBC metastatic triple negative breast cancer mTPI modified toxicity probability interval mTTP median time to progression MUC1 mucin 1, cell surface associated N/A not applicable NAb neutralizing antibody NCI National Cancer Institute CCI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 146Abbreviation Term NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events NHPs nonhuman primates NK natural killer NSCLC non-small cell lung cancer OBD optimal biological dose OR Objective Response or Overall Response ORR o bjective response rate OS overall survival PCD primary completion date PD pharmacodynamics PD progressive disease PD-1 programmed death – 1 PD-L1 programmed death – ligand 1 pDNA Plasmid deoxyribonucleic acid PET positron emission tomography PFS Progression-Free Survival PFS prefilled syringe PI principal investigator PK Pharmacokinetic PGx pharmacogenomics PP per protocol PR partial response PR progesterone receptor PrCa prostate cancer PrCaVBIR Prostate Cancer Vaccine- based Immunotherapy Regimen PS performance status PSA Prostate specific antigen PSCA Prostate stem cell antigen PSMA Prostate specific membrance antigen pT Target probability PT prothrombin time PTT partial thromboplastin time QD every day QT time between the start of the Q wave and the end of the T wave QTcF QT interval with Fridericia's correction QxW Every x# of Weeks, ie, Q2W, Q4W, Q6W, Q12W) RCC renal cell carcinoma RD Response/Remission Duration RECIST Response Evaluation Criteria in Solid TumorsCCI PF-06936308 C3621001Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 147Abbreviation Term RET rearranged during transfection RFS Rela pse-Free Survival ROS1 ROS proto- oncogene 1, receptor tyrosine kinase RP2D recommended Phase 2 dose RR response rate SAE serious adverse event SAP statistical analysis plan SARS-CoV2 severe acute respiratory syndrome coronavirus 2 SC Subcutaneous SCCHN squamous cell carcinoma of the head and neck SCLC small cell lung cancer SD single dose / stable disease SGOT serum glutamic-oxaloacetic transaminase SGPT serum glutamic- pyruvic transaminase SOA Schedule of Activities SOP standard operating procedure SRSD single reference safety document T1/2 terminal elimination half-life Tmax time to maximum plasma concentration Tbili total bilirubin TAAs tumor associated antigens TBR tumor background ratio TERT telomerase reverse transcriptase TILs tumor infiltrating lymphocytes TKIs tyrosine kinase inhibitors TDS-IM (Ichor) Intramuscular TriGrid Delivery System TNBC triple negative breast cancer TRAEs treatment-related adverse events TRK tyrosine receptor kinase TSH thyroid stimulating hormone TTP time to progression ULN upper limit of normal UPM unit probability mass US United States USPI United States Package Insert UVB ultraviolet B VBIR-2 Vaccine- based immunotherapy regimen - 2 VP viral particles Vz/F volume of distributionCCI CCI PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 148Abbreviation Term WBC white blood cell WHO World Health Organization WT wild-type PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 149Appendix 2.ECOG Performance Status Grade ECOG Performance Status 0 Fully active, able to carry on all pre -disease performance without restriction. 1 Restricted in phy sically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work.